IBA Confirms 2025 REBIT Guidance of at Least €25 Million
IBA (Ion Beam Applications SA) has reaffirmed its financial guidance for the full year 2025, projecting at least €25 million in Group REBIT, supported by strong operational control and a positive contribution from its Proton Therapy segment. Equipment order intake reached €195 million as of the third quarter of 2025, marking a 6% increase compared to the previous year, with IBA Technologies showing particularly robust growth at +22%. The company's equipment and services backlog remains stable at €1.3 billion, with sustained conversion rates. IBA also reiterated its mid-term outlook, targeting normalized revenue growth of 5-7% CAGR, operating expenses up to 30% of sales annually, and a REBIT margin of around 10% of revenue by 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IBA - Ion Beam Applications SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001139905-en) on November 20, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。